

Business Standard

Biocon-Bentley pact

Biocon has signed a product
licencing agreement with
Bentley Pharmaceuticals Inc.
Page 24

Business Standard

Biocon, Bentley Pharma in product licensing pact

OUR CORPORATE BUREAU
Mumbai, 16 November

Pharma major Biocon has signed a product licensing agreement with Bentley Pharmaceuticals, a speciality pharmaceutical company in Europe, for the latter's intranasal spray formulation for administering insulin. The license agreement covers 85 countries granting Biocon exclusive as well as co-exclusive rights to develop and market throughout Asia, Africa, and the Middle East.

Bentley has also signed a long-term insulin raw material (API) sourcing agreement with Biocon. The API sourcing

arrangement would provide Bentley and its licensees, with a competitive supply of insulin from Biocon for worldwide markets.

Also, Biocon and Bentley will work together in the clinical development of the intranasal insulin product to meet the requirements of various international regulatory authorities including USA, EU and rest of the world. The two partners will share the cost of clinical development and regulatory filings in their respective territories. However, the terms of the agreement were not disclosed.

Biocon chairperson and man-

aging director Kiran Mazumdar Shaw, said that her company believed that non-injectable insulins will drive the future of diabetes therapy.

"Along with our own program in oral delivery of insulin, this development agreement will give us the breadth of opportunity to straddle the entire domain of non-injectable insulin delivery. As one of the largest producers of insulin, this cooperation is of great strategic importance to us," she added.

At present, Biocon has a broad product portfolio of recombinant biotherapeutics, statins and immuno-suppressants.